Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
Body fat percentage greater than 30% for males and 40% for females
Android to gynoid fat ratio greater than 1.0
Currently eligible for GLP-1 therapy
No diagnosis of Type II diabetes
You may not be if
Presence of abnormal ECG findings, including arrhythmias or ischemic changes
Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg
Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload
VO₂ max below 15 ml/kg/min
Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads
Any contraindications to exercise as defined by ACSM guidelines
Musculoskeletal limitations that prevent safe participation in exercise
Clareo Health | Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1
